Pilot Feasibility Study on 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Patients With Liver Metastases
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases
Stanford is now accepting new patients for this trial.
- Aya Kamaya, MD
- Sanjiv Sam Gambhir, MD, PhD
- George A. Fisher Jr.
- Amelie Lutz
- Dimitre Hristov
- Juergen K. Willmann, M.D.
- procedure : dynamic contrast-enhanced ultrasound imaging
Ages Eligible For Study:
- Provides written informed consent and is willing to comply with protocol requirements - Has colon cancer with liver metastases - Has at least 1 metastasis (target lesion) and is scheduled for neo-adjuvant chemotherapy prior to eventual surgery - Detected by other imaging modalities (including computed tomography [CT] and magnetic resonance tomography [MRT]) performed for routine staging examination of patients - Liver lesions with no previous therapy - Must have at least several months life expectancy - No Eastern Cooperative Oncology Group (ECOG) or performance status will be employed - Has at least 1 colon metastasis: - Detected during staging examinations - In subjects with known history of colon malignancy - Will undergo neo-adjuvant chemotherapy for liver metastases - Ability to understand and the willingness to sign a written informed consent document